Movetis Takes GI from J&J

VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.

VCs—particularly those in Europe—love pre-cooked start-ups and one of the best places to find them is within Big Pharma. So it wasn’t that surprising to see Belgium-based Movetis NV raise a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson . [See Deal] The round—led by Sofinnova Partners and Life Sciences Partners—overshadows all of 2006’s drug discovery Series As and confirms investors’ continued appetite for lower-risk, closer-to-market ventures. (Another Johnson & Johnson offshoot, delivery firm Macroflux Corp., raised $75 million in October 2006 [See Deal].) A smaller round for Movetis was originally planned, notes Antoine Papiernik, managing partner at Sofinnova, but "demand was so big that we pushed it up." (See "The A List: 2006’s Trend-Shaping Series A Financings," START-UP, January 2007 Also see "The A-List: 2006's Trend-Shaping Series A Financings" - Scrip, 1 January, 2007..)

The reasons: Movetis has a deep pipeline and an even deeper management bench. The start-up begins life with four clinical...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By 

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Post-BIO Podcast: Thoughts From The Frontlines

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.